Opening up about patient engagement
November 9, 2021 | patient engagement
Read the third blog of the series looking at key barriers to effective patient engagement in pharma
Inspired by this year’s Patient Centricity and Engagement Conference, Philippa Pristerà uses this mini blog series to reflect on key barriers to patient engagement raised during the event, and share tips and guidance on how to overcome them, collated from her own experience and those shared by speakers from the day.
Opening up about patient engagement
Two patient advocates who spoke at the conference both described pharma as “secretive”. It seemed to stem from the lack of transparency and communication around how and when they would be engaged, and when they couldn’t be. One had recently been stopped from attending a conference tailored for healthcare providers, but no one explained to her why.
This kind of ‘blocking’ can create a feeling of secrecy and depreciates industry messages that they see ‘patients as partners’. She also made the brilliant point that pharma companies do very little to communicate the fact that patients can get involved with their work – “I see the good side of pharma, but you don’t show it!”.
Health research organisations, academic research centres and charities make ‘How to get involved’ a prominent statement on their websites. But pharma companies don’t often showcase the breadth and depth of their patient engagement activity to the public and do even less to provide easy paths for other people to get involved. There are challenges at all stages of research and medicine development, but so few of them get voiced to patient groups to help solve them.
Regulations within the pharma industry may make it difficult to maintain an open dialogue at every step of a medicine’s development. But, encouraging regular communication with patients and being open about where R&D is at, and the shared challenges that exist could be adopted by all.
Fix it by…
- Shouting about your patient engagement. You do more than people know, so open up and be transparent about the engagement activity that is going on
- Creating opportunities for people to get involved in an open and inclusive way. Let people know what issues you are facing and how they can help
- Committing time and resource to frequent communication. This includes sharing more about your research activity and issues you face, sending regular updates for shared projects, and providing a continued point of contact for ad hoc check-ups
- Providing feedback on the project so patients know their contribution makes a difference. This makes them feel valued, demonstrates a company’s commitment to act on their insights, and reinforces positive feelings that will make them more likely to engage with future work and even inspire others to do the same
Missed a post in the series? Catch-up here:
In need of further guidance?
- The Patient Focused Medicines Development team have recently launched a new quality framework that can be used as both a planning tool and assessment tool to ensure you are carrying out high-quality, meaningful engagement.
- For something less focused on medicine development or medtech, check out the UK Standards for Public Involvement, which were co-produced by a UK-wide partnership to improve the quality and consistency of public involvement in research.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Another year, another B!
Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters…
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.
Clinical trial considerations: Why diversity matters…
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here’s why diversity matters…
Clinical trial considerations: Why digital matters…
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Clinical trials explained: Why imagery matters…
Recruiting patients for clinical trials is one of pharma’s greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the…
Clinical trials explained: Why health literacy matters…
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take…
Clinical trials explained: Why iconography matters…
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial…
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
Using generative AI in healthcare comms – our promise to our clients
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when…